Description
Overview
EGFR inhibitor for advanced lung cancer
Product Details
ERLOTINIB (Taro) 150 mg is indicated as first-line therapy in EGFR mutation-positive NSCLC. It interferes with tumor cell proliferation and survival by inhibiting EGFR tyrosine kinase activity.
Key Benefits
- Clinically used and widely prescribed
- Supports effective symptom management
- Quality-controlled pharmaceutical product
How to Use
Use this medication exactly as prescribed by your healthcare provider. Dosage and duration depend on your condition and response to treatment.
Important Information
- Prescription may be required
- Consult your doctor before use
- Read the patient leaflet for full safety information
Reviews
There are no reviews yet.